AG Mednet Addresses Cardiovascular Trial Needs for Data Collection and Quality
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. By allowing meta-data to be assigned to non-DICOM modalities , this provides for better quality data and less delays for modalities that do not yet conform to the DICOM standard. These include Holter data, spectral domain OCT and others.
For sites participating in AG Mednet-based trials, the imaging submissions remain consistent across the DICOM and non-DICOM data sets. For sponsors, CROs and core labs, non-DICOM modalities are delivered to a file system-based infrastructure, while DICOM modalities are delivered either to a standard DICOM environment, or the same file system-based infrastructure.
You can read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
